Lantern Pharma Launches ZetaOmics, an AI-Powered Computational Biology Platform

Lantern Pharma (NASDAQ: LTRN), a precision oncology company leveraging artificial intelligence, has announced the launch of ZetaOmics, a computational biology module integrated into its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across various cancer types, according to a press release.

Initially available through an early-access program for select academic, industry, and company collaborators, ZetaOmics aims to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility. The company stated that the platform combines 14 specialized tools that can autonomously design, execute, and validate biological analyses, detect potential flaws in experimental design, and generate publication-quality results with a complete audit trail.

This launch expands the commercial opportunity for withZeta.ai beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers, and contract research organizations through subscription-based offerings and strategic collaborations. Lantern Pharma believes this represents a new revenue stream for the company.

Lantern Pharma is a clinical-stage precision oncology company that uses AI, machine learning, and its proprietary RADR platform to develop cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.

The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. More details about the launch can be found in the full press release at https://ibn.fm/9sIIl.

The implications of this announcement are significant for the field of precision oncology. By providing an AI-driven platform that automates complex bioinformatics analyses, Lantern Pharma is positioning itself to accelerate cancer research and drug development. The ability to autonomously design and execute biological analyses with enhanced reproducibility could reduce the time and cost associated with traditional research methods. Furthermore, the expansion of withZeta.ai into a subscription-based model opens up new commercial avenues and could democratize access to advanced computational tools for a wider range of research institutions and companies.

For investors, the latest news and updates relating to Lantern Pharma are available in the company’s newsroom at https://ibn.fm/LTRN.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lantern Pharma Launches ZetaOmics, an AI-Powered Computational Biology Platform.

The post Lantern Pharma Launches ZetaOmics, an AI-Powered Computational Biology Platform appeared first on citybuzz.